Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Exocyclic imine compound containing benzo five-membered heterocycle, preparation method and application of exocyclic imine compound

A compound and drug technology, applied in the field of drugs related to thrombotic diseases, can solve problems such as high bleeding risk

Active Publication Date: 2012-10-31
TIANJIN INSTITUTE OF PHARMA RESEARCH
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The disadvantage of these drugs is the greater risk of bleeding

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Exocyclic imine compound containing benzo five-membered heterocycle, preparation method and application of exocyclic imine compound
  • Exocyclic imine compound containing benzo five-membered heterocycle, preparation method and application of exocyclic imine compound
  • Exocyclic imine compound containing benzo five-membered heterocycle, preparation method and application of exocyclic imine compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Example 1 1-[3-tert-butyl-4-methoxy-5-(4-methylpiperazin-1-yl)phenyl]-2-(5,6-diethoxy-2,3-di Hydrogen-3-iminobenzo[d]isoxazol-2-yl)ethanone hydrobromide

[0038]

[0039] A. 5,6-diethoxy-2,3-dihydro-3-iminobenzo[d]isoxazole

[0040]

[0041] A 50mL round bottom flask was added with 2.07g (10mmol) of 4,5-diethoxy-2-hydroxybenzonitrile and 20mL of anhydrous methanol, the resulting mixture was stirred at room temperature, and then 0.56g (10mmol) of solid KOH was added , continued to stir for 5 minutes and then evaporated to dryness on a rotary evaporator, and the obtained residue was dried at room temperature on a vacuum oil pump for 1 hour. To the obtained solid was added 10 mL of dry DMF, stirred at room temperature, and then O-(2,4,6-trimethylbenzenesulfonyl)hydroxylamine was added, and the resulting mixture was stirred overnight at room temperature. TLC showed the reaction was complete.

[0042] The reaction mixture was cooled and poured into 200 mL of ice w...

Embodiment 2

[0045] Example 2 1-[3-isopropyl-4-methoxy-5-(4-methylpiperazin-1-yl)phenyl]-2-(5,6-diethoxy-2,3-di Hydrogen-3-iminobenzo[d]isoxazol-2-yl)ethanone hydrobromide

[0046]

[0047] In a 50mL round-bottomed flask, add 1.56g (7mmol) of 5,6-diethoxy-2,3-dihydro-3-iminobenzo[d]isoxan prepared above according to Example 1 oxazole and 2.59 g (7 mmol) of 3-isopropyl-4-methoxy-5-(4-methylpiperazin-1-yl)-ω-bromoacetophenone were dissolved in 20 mL of dry THF. The resulting mixture was stirred overnight at room temperature, and the resulting yellow cloudy system was filtered with suction, and the solid was collected and washed with a small amount of dry THF. The obtained filter cake was vacuum-dried at room temperature to obtain 1-[3-isopropyl-4-methoxy-5-(4-methylpiperazin-1-yl)phenyl]-2-(5, 6-diethoxy-2,3-dihydro-3-iminobenzo[d]isoxazol-2-yl)ethanone hydrobromide, off-white solid. ESI-MS, m / z=511 ([M+H] + ).

Embodiment 3

[0048] Example 3 1-[3-tert-butyl-4-methoxy-5-(4-methylpiperazin-1-yl)phenyl]-2-(5,6-diethoxy-1,3-di Hydrogen-1,1-dimethyl-3-imino-2H-isoindol-2-yl)ethanone hydrobromide

[0049]

[0050] A. 4,5-diethoxy-2-(1-methylvinyl)benzonitrile

[0051]

[0052] A 100 mL round bottom flask was charged with 2.85 g (10 mmol) of 1-bromo-2-(1-methylvinyl)-4,5-diethoxybenzene, 1.79 g (20 mmol) of CuCN and 30 mL of dry DMF , and the resulting mixture was stirred at reflux for 5 hours under nitrogen atmosphere. TLC showed the reaction was complete.

[0053] The reaction mixture was slowly poured into 200 mL of ice water, stirred, extracted with 50 mL×3 dichloromethane, and the extracted organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. The desiccant was removed by suction filtration, and the obtained filtrate was evaporated to remove the solvent on a rotary evaporator, and the obtained residue was purified by column chromatography to ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicines relevant to thrombotic diseases, in particular to a PAR (protease activated acceptor)-1 antagonist with an exocyclic imine structure containing benzo five-membered heterocycle, a preparation method of the PAR-1 antagonist, a medicine composition containing the PAR-1 antagonist and application of the PAR-1 antagonist to medicines for treating the thrombotic diseases. R1, R2 and R3 are independently selected from alkyl groups of C1, C2, C3, C4 and C5, and X is selected from O and C(CH3)2.

Description

technical field [0001] The invention relates to the field of drugs related to thrombosis diseases. Specifically, the present invention relates to a class of PAR-1 antagonists with a benzo five-membered heterocyclic exoimine structure, a preparation method thereof, and a pharmaceutical composition containing them, which have a therapeutic effect on thrombotic diseases. Background technique [0002] Protease Activated Acceptor-1 (PAR-1) is a new target of anti-platelet antithrombotic drugs discovered recently. Protease-activated receptor 1 is also called thrombin receptor. After thrombin is activated by the coagulation chain, it acts on platelets through PAR-1 receptors to activate platelets, causing platelet aggregation and causing thrombus and coagulation. The thrombus induced by PAR-1 is rich in platelet components, which is the main cause of arterial thrombus. PAR-1 antagonists can block thrombin from activating platelets, thereby blocking arterial thrombus formation, an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D261/20C07D209/40A61K31/496A61P7/02
Inventor 赵桂龙吴疆徐为人苗华明邵华汤立达谭初兵张士俊龚珉
Owner TIANJIN INSTITUTE OF PHARMA RESEARCH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com